New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel c

[News]

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.

More... (https://www.news-medical.net/news/20181114/New-anti-HER2-drug-shows-promising-anti-tumor-activity-in-gullet-stomach-and-bowel-cancers.aspx)